Amanda Strommen1, Amanda L Hurst1, Donna Curtis2, Mark J Abzug2. 1. Children's Hospital Colorado Department of Pharmacy. 2. Department of Pediatrics, Section of Pediatric Infectious Diseases and Epidemiology, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO.
Abstract
BACKGROUND: Posaconazole is a broad-spectrum antifungal used for prophylaxis and treatment of invasive fungal infections. There is no published data to inform prescribers on dosing of the intravenous (IV) formulation in the pediatric population. We describe our experience including dosing, serum concentrations, and tolerability. OBSERVATIONS: Four patients (3 to 9 y) received IV posaconazole for treatment of documented/suspected invasive fungal infections. Patients achieved therapeutic concentrations on daily doses of 8.4 to 12.2 mg/kg and adverse effects were minimal. CONCLUSIONS: Higher dosing per body weight of IV posaconazole may be required in the pediatric population compared with adults to consistently achieve therapeutic concentrations.
BACKGROUND:Posaconazole is a broad-spectrum antifungal used for prophylaxis and treatment of invasive fungal infections. There is no published data to inform prescribers on dosing of the intravenous (IV) formulation in the pediatric population. We describe our experience including dosing, serum concentrations, and tolerability. OBSERVATIONS: Four patients (3 to 9 y) received IV posaconazole for treatment of documented/suspected invasive fungal infections. Patients achieved therapeutic concentrations on daily doses of 8.4 to 12.2 mg/kg and adverse effects were minimal. CONCLUSIONS: Higher dosing per body weight of IV posaconazole may be required in the pediatric population compared with adults to consistently achieve therapeutic concentrations.
Authors: Arathi A Lambrix; Hope D Swanson; Jennifer L Pauley; Allison W Bragg; Delia C Carias; Melissa S Bourque; Yinmei Zhou; Cheng Cheng; William L Greene; Gabriela Maron Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790
Authors: Antonio C Arrieta; Michael Neely; J Christopher Day; Susan R Rheingold; Paul K Sue; William J Muller; Lara A Danziger-Isakov; Julie Chu; Inci Yildirim; Grace A McComsey; Haydar A Frangoul; Tempe K Chen; Victoria A Statler; William J Steinbach; Dwight E Yin; Kamal Hamed; Mark E Jones; Christopher Lademacher; Amit Desai; Kelley Micklus; Desiree Leiva Phillips; Laura L Kovanda; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2021-07-16 Impact factor: 5.191